 |
|
Modules |
|
|
Who's Online |
|
There are currently, 6 guest(s) and 0
member(s) that are online.
You are Anonymous user. You can register
for free by clicking
here |
|
|
Search |
|
|
Languages |
|
Select Interface Language:
|
|
|
|
Welcome to ThisIsMS
Inaugurated in November of 2003, we are
a brand new site dedicated to providing
the latest news, most thorough research
and liveliest community committed to
Multiple Sclerosis and the people it
affects.
This is an entirely unbiased
site
We have no corporate "unrestricted"
grants, no big pharma allegiances, and
no ties to any medical hospital. This
site is funded out of pocket, born out
of a desire to combine interests in web
communities, personal experiences with
people living with MS, and research
skills into an entity that will help
people whose lives have crossed paths
with MS in some way. You will never find
an agenda being pushed here.
Our goal is to provide an
exciting place to learn about how to
deal with, better treat, and ultimately
halt and/or cure multiple sclerosis and
related diseases.
Your presence is our
motivation.
Would you please take a few seconds to
register? It's free, requires no
personal information, and immediately
allows you access to many features of
the site, such as personal e-mail and
posting in the forums, that you won't
have as a guest. It also helps us get an
idea of how many people are using the
site and finding it useful. Thanks!
-The ThisIsMS.com team
|
|
Low Dose Naltrexone
Many of our site
visitors are asking about Low Dose
Naltrexone. This site would have no
purpose unless we brought the
information our visitors wanted, so
please view the entry in the
"Encyclopedia" that describes in
simple language what Low Dose Naltrexone
is, how it works, and how it might help
in the treatment of Multiple Sclerosis.
We also have news stories, downloads,
and
even an entire discussion forum
dedicated to Low Dose Naltrexone, also
known as LDN. Look around, and if you
would like something that you cannot
find on Naltrexone or any other
treatment, please just
drop us a line and we will do our
best to find it and make it available
for you. Thanks for visiting. |
|
 |
2003 Medical Year in Review:
For MS, mentions Antegren +
Blood Tests |
 A
great story by the
Associated Press about
the 2003's major
happenings in health.
There's a tidbit near
and dear to our hearts:
-Scientists
developed the first
blood test that reveals
whether people with
neurological problems,
such as tingling or
blurred vision, will
soon develop multiple
sclerosis. An
experimental drug called
Antegren was also shown
to cut the number of
relapses from the
disease in half.
However, these blood
tests they refer to are
just not very well
accepted yet... and go
Antegren! RELEASE IT
NOW! The whole article
is really interesting,
read it by clicking
"Read More" below.
|
|
|
Posted by
Administrator
on Friday, December 12 @ 13:50:34 CST
(43 reads)
(Read
More... | 7997 bytes more |
comments?
| Score: 0)
|
|
|
Clinical
Trials: Genzyme
Announces Start of Phase 1 Trial
of Genz-29155 for Multiple
Sclerosis |
 Add
another drug to the
pipeline!
Genzyme Corporation
announced today that
physicians have treated
the first participants
in a Phase 1 clinical
trial to test the safety
of Genz-29155, a small
molecule developed by
Genzyme for the
treatment of multiple
sclerosis.
...
Genz-29155, which was
discovered through high
throughput screening at
Genzyme, has shown an
ability in vitro to
inhibit some, but not
all, of the activities
of tumor necrosis factor
(TNF), a protein active
in the regulation of
certain immune
responses. In vivo,
Genz-29155 has shown
potential to have an
effect not only in
models of multiple
sclerosis, but of other
immune- mediated
diseases as well.
|
|
|
Posted by
Administrator
on Friday, December 12 @ 13:37:33 CST (1
reads)
(Read
More... | 6027 bytes more |
comments?
|
Clinical Trials | Score: 0)
|
|
|
Clinical
Trials: Tularik
Initiates Phase 2 Clinical Trial
of T487 in Psoriasis (MS to
follow?) |
| Although
they are going after
Psoriasis first, this
drug has potential for
treating Multiple
Sclerosis down the
road...
Tularik Inc. today
announced the initiation
of a Phase 2 efficacy
and safety study with
T487 for the treatment
of patients with
psoriasis. T487 is an
orally-administered
therapy that has a novel
mechanism of action and
is expected to reduce
inflammation in
conditions such as
psoriasis.
T487 acts by binding
to CXCR3, a receptor
found on the surface of
lymphocytes. The binding
of T487 to CXCR3
inhibits the migration
of lymphocytes into
inflamed tissue. Thus,
T487 is expected to
provide symptomatic
relief and block the
progression of diseases
such as rheumatoid
arthritis, inflammatory
bowel disease, multiple
sclerosis and psoriasis.
In preclinical studies,
T487 blocked immune cell
migration and
demonstrated excellent
potency, high
selectivity and good
oral bioavailability. In
Phase 1 studies, all
doses of T487 were
well-tolerated and no
serious adverse events
were observed.
|
|
|
Posted by
Administrator
on Wednesday, December 10 @ 15:14:17 CST
(4 reads)
(Read
More... | 4947 bytes more |
comments?
|
Clinical Trials | Score: 0)
|
|
|
Research:
AVR118 Suppresses Progression of
MS in Animal Model |
| Advanced
Viral Research Corp.
today announced that
administration of its
novel immunomodulator
AVR118 (formerly known
as Product R) in animals
with induced
experimental allergic
encephalomyelitis (EAE)
suppressed progression
of this demyelinating
neurological disease.
This animal model,
developed by the
Weizmann Institute of
Science in Rehovot,
Israel, serves as a
potential model for the
use of AVR118 in the
treatment of the human
auto-immune
demyelinating disease,
multiple sclerosis (MS). |
|
|
Posted by
Administrator
on Tuesday, December 09 @ 14:16:25 CST
(10 reads)
(Read
More... | 4375 bytes more |
comments?
|
Research
| Score: 0)
|
|
|
Clinical
Trials: First Patient
Enrolled in new Betaferon Study |
| Schering
AG, Germany announced
today that the first
multiple sclerosis (MS)
patient has entered the
second phase of the
BEYOND trial. This
compares the efficacy of
a new, higher-dose
Betaferon® (500 mcg)
with Betaferon 250 mcg
and glatiramer acetate
(Copaxone) in patients
with relapsing-remitting
MS. Recently, the
company announced
positive safety and
tolerability data from
the first phase of the
study program examining
Betaferon 250 mcg and
Betaferon 500 mcg. |
|
|
Posted by
Administrator
on Tuesday, December 09 @ 14:02:53 CST
(7 reads)
(Read
More... | 4342 bytes more |
comments?
|
Clinical Trials | Score: 0)
|
|
|
New Test ''Pinpoints Multiple
Sclerosis Progression'' |
| MS
can be debilitating.
Scientists have
developed a way to
measure the severity of
a patient's multiple
sclerosis and gauge how
well drugs are working.
The researchers at
New York University hope
it will improve both
diagnosis and treatment
of the disease.
The technique
measures the amount of a
key chemical that is
found in lower quantity
than usual in the brain
cells of MS patients.
Mike O'Donovan, chief
executive of the MS
Society, said: "This is
an encouraging addition
to the growing range of
magnetic resonance
measuring techniques
which are helping to
develop and monitor new
treatments for this
dreadful disease."
Click "read more" to
see the entire article
|
|
|
Posted by
Administrator
on Sunday, December 07 @ 22:01:44 CST
(24 reads)
(Read
More... | 4168 bytes more |
comments?
| Score: 4)
|
|
|
Treatments:
Sativex (Marijuana Treatment for
MS) Update |
 Some
news on Sativex from
Friday, December 5th:
GW Pharmaceuticals
added 19p to 177 1/2p
after broker Evolution
Beeson Gregory repeated
'buy' advice, and told
clients that recent
falls had been overdone.
It expects
regulatory approval
early next year for
Sativex, GW's treatment
for multiple sclerosis,
which it saw boosting
shares by up to 50%.
(source)
Which is an
interesting contrast to
the last news we heard
about Sativex from the
company itself on
November 28, 2003:
"GW Pharmaceuticals
have warned investors
that their new drug
Sativex may yet have to
wait until next autumn
for approval from the
government's medicines
regulator. The news is a
blow not only to GW but
also to Multiple
Sclerosis sufferers who
have long been
campaigning to be
allowed to use a
cannabis drug to relieve
their symptoms. Trial
data has shown that
Sativex is an effective
treatment for bladder
problems and muscle
stiffness but GW has
also applied for
approval for the drug to
treat neuropathic pain.
It is this issue where
the drug's approval has
stumbled. Neuropathic
pain, pain caused by a
diseased or damaged
nervous system, is
widely viewed as
impossible to treat so
such an indication would
be a massive
breakthrough for GW.
Unfortunately the MHRA
are likely to ask for
more trials next year
before they give such a
groundbreaking approval.
A spokesman for GW
said "The process is
continuing as expected.
There is a month to go
and we are confident of
getting approval. We
have always said the
timing was going to be
in the hands of the
regulator"."
(source)
You can check the
quote for GW
Pharmaceuticals (on the
London Stock Exchange)
here
Note: View our
encyclopedia entry on
Sativex
here
|
|
|
Posted by
Administrator
on Sunday, December 07 @ 16:51:36 CST (4
reads)
(comments?
|
Treatments
| Score: 0)
|
|
|
Rates of AutoImmune Disease
doubled in last 40 years |
| From
this month's Newsweek:
When the Body
Attacks Itself
Autoimmunity:
Rates of immune
disorders like Crohn’s
and MS more than doubled
in 40 years
"The immune system is
a thing of beauty—subtle
enough to distinguish
dangerous invaders like
viruses from benign
interlopers such as
food; clever enough to
recognize when the
body’s supposedly
friendly cells turn
cancerous and should be
eliminated. But the
immune system can also
go seriously awry. When
it begins mauling
healthy tissues, the
result can be any one of
80 autoimmune diseases
such as lupus or
rheumatoid arthritis.
“It’s the price we pay
for having such a
dynamic, finely balanced
system,” says
immunobiologist Jeffrey
Bluestone, director of
the Immune Tolerance
Network at the
University of
California, San
Francisco."
click "read more"
below to get the rest of
the article...
|
|
|
Posted by
Administrator
on Wednesday, December 03 @ 22:26:19 CST
(11 reads)
(Read
More... | 5936 bytes more |
comments?
| Score: 0)
|
|
|
News:
UK Govt. Study: ''Seven
alternative remedies might be
worth trying'' |
 We
just got the full story!
This is exciting info--
finally some sort of
government-backed study
on alternative
therapies-- this could
really help cut out some
of the overwhelming task
of sorting through
literally hundreds of
options when considering
non-standard treatments.
United Kingdom
Government watchdog
breaks new ground by
giving cautious
endorsement of some
complementary medicines
in treating multiple
sclerosis
The role of
complementary therapies
such as fish oils,
reflexology and t'ai chi
in treating disease are
recognised for the first
time in official NHS
guidance published
today.
Click "read more" to
get the full article...
in the meanwhile, we're
working on getting the
actual report for you to
download, as well as
updating our encylopedia
to include information
on all the recommended
alternative Multiple
Sclerosis therapies...
Note: We're
really proud of the fact
that we are the first
Multiple Sclerosis site
to carry this story! We
uphold our promise to
bring you the latest
breaking news on
Multiple Sclerosis every
day, free of charge or
bias.
|
|
|
Posted by
Administrator
on Monday, November 24 @ 22:37:47 CST
(89 reads)
(Read
More... | 6502 bytes more |
comments?
|
News
| Score: 5)
|
|
|
BioGen Taking Steps towards
Antegren Production |
| This
is a business story
about how Biogen is
moving some of its
manufacturing facilities
from California to a
place called Research
Triangle Park, in North
Carolina. The
interesting paragraph
is:
"The company also
plans to use RTP to
manufacture Antegren, a
treatment of multiple
sclerosis and Crohn's
disease that is in Phase
III trials - the final
approval stage. Trial
batches are being run at
RTP, and commercial
production could begin
in mid-2006, says
Brockelman."
Amy Brockelman, the
person quoted, is a
spokeswoman for Biogen
Idec
ThisIsMS.com feels
that this could be
(cautiously) viewed as a
very positive step that
Biogen is taking public
steps towards production
of Antegren. At the very
least, the trials cannot
be failing
spectacularly, or they
wouldn't bother with
such a move.
|
|
|
Posted by
Administrator
on Monday, November 24 @ 14:14:36 CST
(220 reads)
(Read
More... | 3802 bytes more |
comments?
| Score: 5)
|
|
|
FDA-Approved
Drugs:
Brain-protecting Protein Boosted
by Multiple Sclerosis Drug |
 Copaxone,
a drug used to treat
multiple sclerosis, has
been found to stimulate
immune system cells to
produce a
brain-protecting
protein. |
|
|
Posted by
Administrator
on Friday, November 21 @ 18:32:48 CST
(30 reads)
(Read
More... | 3049 bytes more |
comments?
|
FDA-Approved Drugs | Score: 0)
|
|
|
Research:
Simple Anti-Inflammatories May
Help Neuron Replacement |
 Two
studies shed new light
on the role of brain
inflammation in diseases
such as Alzheimer's and
other dementias. |
|
|
Posted by
Administrator
on Monday, November 17 @ 20:38:52 CST
(46 reads)
(Read
More... | 3974 bytes more |
1 comment |
Research
| Score: 0)
|
|
|
Research:
Blocking Proteins Could Modulate
Multiple Sclerosis, Alzheimer's
& Parkinsons |
|
Understanding the
signals to turn on
specific genes in the
brain with proteins
might enable the
modulation of an immune
attack to the brain like
that of Multiple
Sclerosis (MS),
according to a study
presented here November
8th at the Society for
Neuroscience 33rd Annual
Meeting.
|
|
|
Posted by
Administrator
on Monday, November 17 @ 20:32:26 CST
(25 reads)
(Read
More... | 3682 bytes more |
comments?
|
Research
| Score: 0)
|
|
|
ThisIsMS
Related: Oh, the
possibilities... |
How
can you help make this
the most rewarding
Multiple Sclerosis site
on the internet?
Well, you can help by
bookmarking us, linking
to our site and, more
than anything else,
paying us a daily visit
and participating in the
many things available to
you here:
Our first promise is to
post the latest
MS-related news here,
updated daily. You won't
have to scurry around
the web looking for
information or wait for
friends to send you
articles anymore, it
will all be right here.
In short, we look
forward to watching this
site grow with your
help. Especially while
we are young, you have
an opportunity to truly
make this site yours.
Thank you for coming.
|
|
|
Posted by
Administrator
on Thursday, November 13 @ 19:49:22 CST
(18 reads)
(comments?
|
ThisIsMS Related | Score: 4)
|
|
|
|
|
Login |
|
|
Don't have
an account yet? You can
create one. As a registered user you
have some advantages like theme manager,
comments configuration and post comments
with your name. |
|
|
Survey |
|
|
Latest Forum Posts |
|
|
Old Articles |
|
|
Categories Menu |
|
|
Big Story of Today |
|
|
Information |
|
|
This site is privately funded by
individuals interested in fighting
multiple sclerosis.
There are no corporate grants, medical
center affiliations, or overbearing
advertisements, providing a truly
independent online community for MS.
Note that all medical decisions
should be made with the consent of your
doctor. |
|
|
|
